By Peter Geschek:Even with the best cancer drugs, doctors are forced to switch from one therapy to the next as the tumors rapidly develop resistance.A new wave of immunotherapy drugs, in the spotlight of the upcoming ASCO (American Society of Clinical Oncology) meeting, promises to produce longer-lasting remissions.
By Peter Geschek:In February Merck (MRK) has signed three collaboration agreements with Amgen (AMGN), Incyte (INCY) and Pfizer (PFE), to conduct separate clinical trials combining Merck's anti-PD-1 therapy MK-3475
By Investment Directions: We had great news today (Thursday), but the response was tepid. Rather than being disappointed or dismissing the news, here is why we should be excited at both the developments and the investment potential it opens up.
Roche Holding AG (RHHBY) announced today that the investigational drug, cobimetinib, proved effective in treating melanoma skin cancer when used with another of the company’s drugs, Zelboraf. Phase III results, with 495 patients in the study, revealed that using the drug medley helped people with advanced melanoma live longer without the disease worsening. Detailed data will be presented at an upcoming medical meeting.
Prohost Biotech submits:One year ago, an anaplastic lymphoma kinase (ALK) inhibitor called crizotinib developed by Pfizer (PFE) for non-small-cell lung cancer demonstrated it shrank the tumors in most of the 82 patients after two months of treatment.